Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of NXT007 versus emicizumab prophylaxis in hemophilia A
MOH_2026-03-05_015701Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hemophilia A comparing NXT007 prophylaxis with Emicizumab prophylaxis (2 arms). Primary endpoint: Efficacy based on treated bleeds. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
zemocimigemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2026-03-05_015701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-05_015701.